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Abstract
Background: Drug-metabolizing enzymes (DMEs) inhibition based drug-drug interaction and herb-drug interaction
severely challenge the R&D process of drugs or herbal ingredients.
Objective: To evaluate the inhibition potential of  wogonin (an important flavonoid isolated from the root of  Scutellaria
baicalensis) towards one of the most important phase II DMEs, UDP-glucuronosyltransferase (UGT) 1A9.
Methods: Both recombinant UGT1A9-catalyzed 4-methylumbelliferone (4-MU) glucuronidation reaction and human liver
microsomes (HLMs)-catalyzed propofol glucuronidation reaction were used as two different probe reactions.
Results: Wogonin noncompetitively inhibited recombinant UGT1A9-catalyzed 4-MU glucuronidation, and exerted
competitive inhibition towards HLMs-catalyzed propofol glucuronidation. The inhibition kinetic parameters (K
i
) were
calculated to be 3.2 µM and 52.0µM, respectively.
Conclusion: Necessary monitoring was needed when wogonin was co-administered with the clinical drugs mainly undergoing
UGT1A9-mediated glucuronidation elimination. Additionally, probe reactions-dependent inhibition of  wogonin towards
the activity of UGT1A9 should be paid attention when translating these in vitro data into in vivo situation.
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Since the beginning of the herbs’ utilization from
ancient times, the utilization of herbal medicines has
a history of about 4000 years1. With the increasing
utilization of herbal remedies, more and more cases
on herbal adverse effects are reported. Herb-drug
interaction has been frequently reported, and the co-
administered herbs might affect the pharmacokinetic
behaviouts of many important clinical drugs,
including warfarin, aspirin, digoxin and cisplatin 2.
The drugs can be efficiently eliminated by phase I
and phase II drug metabolizing enzymes (DMEs)-
mediated elimination system. Herbal components can
change the activity of all these DMEs through the
good interaction with them. When these herbs are
co-administered with the drugs mainly undergoing
the DMEs inhibited by herbal components, the
exposed concentration of drugs might exceed the
minimal toxicity dose in the therapeutic window, and
then induce severe toxicity.
The glucuronidation through the conjugation
with glucuronic acid represents the main elimination
pathway of clinical drugs, and the inhibition of this
important pathway might induce the severe drug-
drug interaction. For example, the exposed
concentration of zidovudine (the probe substrate
of UGT2B7) can increase by 31% and 74% due to
the inhibition of glucuronidation pathway by
atovaquone and fluconazole, respectively3,4. Some
previous literatures have indicated that some herbal
components can exhibit the strong inhibition towards
UGT isoforms. For example, the most abundant
flavonoid component quercetin inhibited the activity
of UGT1A1 and UGT1A95. In vitro experiment
showed that the activity of UGT1A1, 1A6, 1A9,
2B7 and 2B15 can be inhibited by silybin 6. The
herbal components deoxyschizandrin and
schisantherin A have been demonstrated to have the
potential to induce herb-drug interaction through the
strong inhibition towards UGT1A3 7. Fang et al.
investigatd the stucture-activity relationship for the
ginsenosides’ inhibition towards UGT isoforms,
elucidating the potential UGTs-inhibition based
ginseng-clinical drugs interactions 8.
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Wogonin, an important flavonoid isolated from
the root of Scutellaria baicalensis Georgi, has been
reported to exhibit multiple biochemical and
pharmacological activities, including antioxidant9,
anti-viral10, antithrombotic11, and anti-inflammatory
activities12. The present study aims to study the
inhibition of wogonin towards one of the most
important UGT isoforms, UGT1A9. In vitro
incubation system was performed. Given that the
probe reactions-dependent behaviour for the
inhibition of DMEs by compounds exists, two kinds
of probe reactions were carried out, including
recombinant UGT1A9-catalyzed 4-
methylumbelliferone (4-MU) glucuronidation and




Wogonin (purity >98%), propofol, alamethicin, 4-
methylumbelliferone (4-MU), 4-
methylumbelliferone-alpha-D-glucuronide (4-
MUG), Tris-HCl, 7-hydroxycoumarin and uridine
5’-diphosphoglucuronic acid (UDPGA) (trisodium
salt) were purchased from Sigma-Aldrich (St. Louis,
MO). The glucuronide of propofol was purchased
from Toronto Research Chemicals (North York,
Ontario, Canada). Recombinant human UGT1A9
expressed in baculovirus-infected insect cells, and
pooled human liver microsomes (HLMs) from 50
donors were obtained form BD Gentest Corp.
(Woburn, MA, USA). All other reagents were of
HPLC grade or of the highest grade commercially
available.
Evaluation of wogonin’s inhibition towards
UGT1A9-catalyzed 4-MU glucuronidation
The inhibition of wogonin towards recombinant
UGT1A9-catalyzed 4-MU glucuronidation was
evaluated as previously described13. The mixture
(200µl total volume) contained recombinant 0.05
mg/ml of UGT1A9, 5 mM UDPGA, 5 mM MgCl
2
,
50 mM Tris-HCl buffer (pH 7.4), and 4-MU (30µM)
in the absence or presence of different
concentrations of  wogonin. Wogonin was dissolved
in DMSO and the final concentration of DMSO
was 0.5% (v/v). After 5 min pre-incubation at 37oC,
the UDPGA was added in the mixture to initiate
the reaction. Incubation time was 30 min for
UGT1A9. The reactions were quenched by adding
100 ìl acetonitrile with 7-hydroxycoumarin (100µM)
as internal standard. The mixture was centrifuged at
20,000×g for 10 min and an aliquot of supernatant
was transferred to an auto-injector vial for HPLC
analysis as previously described 8.
Investigation of wogonin’s inhibition towards
human liver microsomes (HLMs)-catalyzed
propofol glucuronidation
The inhibition of wogonin towards the propofol
glucuronidation catalyzed by human liver
microsomes (HLMs) was evaluated as previously
described 14. In brief, the incubation system contained
0.5 mg/ml human liver microsomes (HLMs), 5mM
UDPGA,5mM MgCl
2
, 25µg/ml alamethicin, 10mM
D-saccharic acid 1,4-lactone, propofol
(approximately K
m
 value) and Tris–HCl buffer
(pH=7.4).
The ultra-fastliquidchromatography(UFLC)-mass
(MS) method was utilized to detect the glucuronide
of propofol. The mobile phase contained CH
3
CN
(A) and water with 0.5% acetic acid (B) with the
following gradient condition: 0–2 min, 95–82% B;
2–7 min, 82–20% B; 7–9.5 min, 10% B; 9.5–12.5
min, 95% B. Column temperature was kept at 37
æ%C. The flow rate was set at 0.3 ml/min and the
injection volume was 10µl. The negative mode was
used, and molecular ions ([M-H]-) 353 and 351 were
employed for propofol glucuronide and the internal
standard 4-MU glucuronide.
Determination of  inhibition kinetic parameters
Inhibition kinetic parameters (K
i
) were determined
utilizing various concentrations of 4-MU (or
propofol) in the presence of different concentrations
of wogonin. Dixon and Lineweaver-Burk (L-B)
plots were adapted to determine the inhibition type,
and second plot of slopes from Lineweaver-Burk





The inhibition of wogonin towards recombinant
UGT1A9-catalyzed 4-MU glucuronidation reaction
was evaluated, and the results were shown in figure
1. Wogonin exhibited dose-dependent inhibition
towards 4-MU glucuronidation (figure 1A), and both
Dixon plot (figure 1B) and Lineweaver-Burk plot
(figure 1C) showed that the inhibition type was best
fit to the noncompetitive inhibition. The second plot
(figure 1D) was used to calculate the inhibition kinetic
parameter (K
i
) to be 3.2 ìM. Furthermore, human
liver microsomes (HLMs)-catalyzed propofol
glucuronidation reaction was employed to evaluate
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the wogonin’s inhibition towards UGT1A9 activity.
Similarly, the concentration-dependent inhibition behaviour
was also observed (figure 2A). The competitive inhibition
type was demonstrated for wogonin’s inhibition towards
HLMs-catalyzed propofol glucuronidation through Dixon
plot (figure 2B) and Lineweaver-Burk plot (figure 2C). The
inhibition kinetic parameter (K
i
) was calculated to be 52.0
ìM (figure 2D).
Figure 1: Wogonin noncompetitively inhibits recombinant UGT1A9-catalyzed 4-methylumbelliferone (4-MU)
glucuronidation.
(A) Dose-dependent inhibition of wogonin towards UGT1A9-catalyzed 4-methylumbelliferone (4-MU) glucuronidation;
(B) Dixon plot of  wogonin’s inhibition towards UGT1A9-catalyzed 4-methylumbelliferone (4-MU) glucuronidation; (C)
Lineweaver-Burk plot of  wogonin’s inhibition towards UGT1A9-catalyzed 4-methylumbelliferone (4-MU) glucuronidation;
(D) Second plot of  wogonin’s inhibition towards UGT1A9-catalyzed 4-methylumbelliferone (4-MU) glucuronidation. The
experiments were performed in duplicate, and data points were given as mean of the duplicate.
Figure 2: Wogonin competitively inhibits human liver microsomes (HLMs)-catalyzed propofol glucuronidation.
(A) Dose-dependent inhibition of wogonin towards HLMs-catalyzed propofol glucuronidation; (B) Dixon plot of
wogonin’s inhibition towards HLMs-catalyzed propofol glucuronidation; (C) Lineweaver-Burk plot of  wogonin’s inhibition
towards HLMs-catalyzed propofol glucuronidation; (D) Second plot of  wogonin’s inhibition towards HLMs-catalyzed
propofol glucuronidation. The experiments were performed in duplicate, and data points were given as mean of the
duplicate.
African Health Sciences Vol 13  Issue 3 September  2013554
Discussion
Several phenolic hydroxyl groups exist in the structure
of wogonin, and previous studies have indicated that
the phenolic hydroxyl groups-containing compounds
are the good substrates of  UGT isoforms, including
arbidol15 and magnolol16. The UGT isoforms
involved in the metabolic elimination of wogonin
have been identified. UGT1A9 was regarded as the
main UGT isoform involved in the glucuronidation
of wogonin in the liver, and UGT1A10 was the
major UGT isoform responsible for wogonin’s
glucuronidation in the intestine17. All these
information indicated the possibly good interaction
between wogonin and UGT1A9.
In this study, wogonin showed inhibitory
potential towards the activity of UGT1A9, regardless
of  the enzyme sources and probe substrates.
However, the inhibition type and potential showed
the difference when selecting difference enzyme
sources and probe substrates. Wogonin
noncompetitively inhibited recombinant UGT1A9-
catalyzed 4-MU glucuronidation, and competitively
inhibited human liver microsomes (HLMs)-catalyzed
propofol glucuronidation reaction. When choosing
UGT1A9-catalyzed 4-MU glucuronidation reaction
as the probe reaction, the inhibition potential was
stronger. This kind of  enzyme sources and probe
substrates-dependent inhibition behaviour has been
observed in the previous literatures18. UGT1A9 is
one of  the most important UGT isoforms in liver,
kidney and intestine, and take part in the metabolism
of  many xenobiotics. For example, UGT1A9 is the
major UGT isoform involved in the ethanol
glucuronidation19. UGT1A9 showed extensive
activity towards the glucuronidation of
acetaminophen20. Additionally, UGT1A9 has been
demonstrated to be responsible for the
glucuronidation of many clinical drugs or drug
candidates, including noscapine and sorafenib21,22.
Therefore, the potential drug-drug interaction exists
for the co-administration of wogonin and the clinical
drugs mainly undergoing UGT1A9-catalyzed
metabolic elimination.
Conclusion
Necessary monitoring was needed when wogonin
was co-administered with the clinical drugs mainly
undergoing UGT1A9-mediated glucuronidation
elimination. Additionally, probe reactions-dependent
inhibition of wogonin towards the activity of
UGT1A9 should be paid attention when translating
these in vitro data into in vivo situation.
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